Pamiparib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Pamiparib
Accession Number
DB14769
Type
Small Molecule
Groups
Investigational
Description

Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).

Structure
Thumb
Synonyms
Not Available
External IDs
BGB-290
Categories
Not Available
UNII
8375F9S90C
CAS number
1446261-44-4
Weight
Average: 298.321
Monoisotopic: 298.122989282
Chemical Formula
C16H15FN4O
InChI Key
DENYZIUJOTUUNY-MRXNPFEDSA-N
InChI
InChI=1S/C16H15FN4O/c1-16-3-2-4-21(16)7-11-13-12-9(15(22)20-19-11)5-8(17)6-10(12)18-14(13)16/h5-6,18H,2-4,7H2,1H3,(H,20,22)/t16-/m1/s1
IUPAC Name
(2R)-14-fluoro-2-methyl-6,9,10,19-tetraazapentacyclo[14.2.1.0^{2,6}.0^{8,18}.0^{12,17}]nonadeca-1(18),8,12(17),13,15-pentaen-11-one
SMILES
C[C@]12CCCN1CC1=NNC(=O)C3=C4C(NC2=C14)=CC(F)=C3

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
58805610
ChEMBL
CHEMBL4112930

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingBasic ScienceTumors, Solid1
1Active Not RecruitingTreatmentFor Patients With Advanced Solid Tumors Failed With Previous Lines of Treatment / Tumors, Solid1
1RecruitingBasic ScienceAdvanced Solid Tumors1
1RecruitingTreatmentGlioblastomas / IDH1 Gene Mutation / IDH2 Gene Mutation / Low Grade Glioma (LGG) / Malignant Gliomas / Recurrent Glioblastoma / Recurrent WHO Grade II Glioma / Recurrent WHO Grade III Glioma / WHO Grade II Glioma / WHO Grade III Glioma1
1RecruitingTreatmentTumors, Solid1
1, 2Active Not RecruitingTreatmentAdvanced High-grade Ovarian Cancer / Advanced Solid Tumors / Triple Negative Breast Cancer (TNBC)1
1, 2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors1
1, 2RecruitingTreatmentIDH1 Mutation / IDH2 Mutation / Recurrent Glioblastoma / Recurrent WHO Grade II Glioma / Recurrent WHO Grade III Glioma1
1, 2RecruitingTreatmentLocally Advanced or Metastatic Solid Tumors1
2RecruitingTreatmentCarcinosarcoma / Ovarian Cancer1
2RecruitingTreatmentHER2-Negative Breast Cancer1
2RecruitingTreatmentHRD / Metastatic Castration-Resistant Prostate Cancer (mCRPC) / Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Homologous Recombination Deficiency (HRD)1
3Active Not RecruitingTreatmentOvarian Cancer1
3Enrolling by InvitationTreatmentAdvanced Malignancies1
3Not Yet RecruitingTreatmentOvarian Cancer1
3RecruitingTreatmentAdvanced or Inoperable Gastric Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0933 mg/mLALOGPS
logP2.03ALOGPS
logP1.39ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)10.28ChemAxon
pKa (Strongest Basic)5.62ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area60.49 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity81.01 m3·mol-1ChemAxon
Polarizability29.89 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:26 / Updated on November 02, 2019 03:26